Kiran Mazumdar-Shaw, the founder of Biocon, has named her niece Claire Mazumdar as her successor, marking a significant step in the company's leadership transition. Claire, 37, is currently the CEO of Bicara Therapeutics, a U.S.-based company focused on innovative cancer therapies, which she led to a market capitalization exceeding $1.6 billion following its public offering on NASDAQ in 2024. Her academic credentials include a degree in biological engineering from the Massachusetts Institute of Technology (MIT), an MBA from Stanford Graduate School of Business, and a PhD in cancer biology from Stanford School of Medicine. Claire's professional experience encompasses venture capital and drug development, having worked with notable firms like Third Rock Ventures and Rheos Medicines.

Biocon is currently undergoing a strategic transformation, merging its generics and biologics divisions while focusing on biosimilars, which account for about 60% of its revenue. As Claire prepares to step into a more prominent role, Kiran has assured that the transition will be gradual, allowing for continuity in leadership. Claire will be supported by a network of family and professional leaders, including her brother Eric Mazumdar, an artificial intelligence expert, and her husband Thomas Roberts from Massachusetts General Hospital. As Biocon enters this new chapter, Claire's low-profile status may soon change as she takes on greater responsibilities.